Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8316477 | 0.89 | BRAF (0.64) | BRAF | |
| SCHEMBL8487628 | 0.88 | BRAF (0.55) | BRAFNTRK1 | |
| SCHEMBL8485805 | 0.86 | BRAF (0.50) | BRAFNTRK1 | |
| SCHEMBL6990834 | 0.83 | BRAF (0.55) | BRAFNTRK1 | |
| SCHEMBL8316098 | 0.82 | ERBB2 (0.56) | BRAF | |
| SCHEMBL8488606 | 0.82 | BRAF (0.52) | BRAFNTRK1 | |
| SCHEMBL8483815 | 0.82 | BRAF (0.54) | BRAF | |
| SCHEMBL8317331 | 0.81 | BRAF (0.56) | BRAF | |
| SCHEMBL8320360 | 0.81 | BRAF (0.56) | BRAF | |
| SCHEMBL8319713 | 0.81 | EGFR (0.66) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | disclosed |
| EP-0885227-A1 | PYRIMIDO 5,4-d]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | Dr. Karl Thomae GmbH (DE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032882-A1 | PYRIMIDO[5,4-d]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | DR. KARL THOMAE GMBH (DE) | 1997-09-12 | — | — | WO | disclosed |